metastatic malignant neoplasm in the colon

The spread of a malignant neoplasm to the colon. This may be from a primary large intestine malignant neoplasm, or from a malignant neoplasm at a distant site.


DNA-directed RNA polymerases I, II, and III subunit RPABC1 isoform 1 (human)

A DNA-directed RNA polymerases I, II, and III subunit RPABC1 isoform 1 that is encoded in the genome of human.


cytochrome P450 2S1

A protein that is a translation product of the human CYP2S1 gene or a 1:1 ortholog thereof.


cytochrome P450 2S1 isoform h2 (human)

A cytochrome P450 2S1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q96SQ9-2.


cytochrome P450 2S1 isoform h1 (human)

A cytochrome P450 2S1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q96SQ9-1.


The stable isotope of aluminium with relative atomic mass 26.98153 and nuclear spin (5)/2.


isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial, transit peptide removed form (human)

An isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial (human) that has had the transit peptide removed. UniProtKB:P50213, 28-366.


isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial isoform 1 (human)

An isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial isoform 1 that is encoded in the genome of human.


isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial isoform 2 (human)

An isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial isoform 2 that is encoded in the genome of human.


Advanced Endometrial Carcinoma

biolink:Disease biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:NamedThing biolink:Entity biolink:ThingWithTaxon

An endometrial carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Advanced Cervical Squamous Cell Carcinoma

Cervical squamous cell carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Advanced Cervical Carcinoma

A cervical carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Advanced Ovarian Carcinoma

An ovarian carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Advanced Microsatellite Stable Ovarian Carcinoma

Microsatellite stable ovarian carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Advanced Microsatellite Stable Endometrial Carcinoma

Microsatellite stable endometrial carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Advanced Cervical Adenosquamous Carcinoma

Cervical adenosquamous carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


probable inactive allantoicase isoform h1 (human)

A probable inactive allantoicase (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q8N6M5-1.


probable inactive allantoicase isoform h2 (human)

A probable inactive allantoicase (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q8N6M5-2.


alanine--tRNA ligase, cytoplasmic isoform h2 (human)

An alanine--tRNA ligase, cytoplasmic (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P49588-2.


alanine--tRNA ligase, cytoplasmic isoform 1 (human)

An alanine--tRNA ligase, cytoplasmic isoform 1 that is encoded in the genome of human.


oxytocin-neurophysin 1 isoform 1 (human)

An oxytocin-neurophysin 1 isoform 1 that is encoded in the genome of human.


serine/threonine-protein kinase WNK4 isoform h2 (human)

A serine/threonine-protein kinase WNK4 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q96J92-2.


Parkinson disease

A progressive degenerative disorder of the central nervous system characterized by loss of dopamine producing neurons in the substantia nigra and the presence of Lewy bodies in the substantia nigra and locus coeruleus. Signs and symptoms include tremor which is most pronounced during rest, muscle rigidity, slowing of the voluntary movements, a tendency to fall back, and a mask-like facial expression.


Parkinson disease 17

Any Parkinson disease in which the cause of the disease is a mutation in the VPS35 gene.


Parkinson disease 21

Any hereditary late onset Parkinson disease in which the cause of the disease is a mutation in the DNAJC13 gene.


autosomal dominant Parkinson disease 8

Any Parkinson disease in which the cause of the disease is a mutation in the LRRK2 gene.


autosomal dominant Parkinson disease 4

A late onset Parkinson disease that has material basis in heterozygous triplication of the alpha-synuclein gene (SNCA) on chromosome 4q22.


Parkinson disease 22, autosomal dominant

Any Parkinson disease in which the cause of the disease is a mutation in the CHCHD2 gene.


autosomal recessive Parkinson disease 14

A rare neurodegenerative disease usually presenting before the age of 30 and which is characterized by dystonia, L-dopa-responsive parkinsonism, pyramidal signs and rapid cognitive decline.


lys-63-specific deubiquitinase BRCC36 isoform h3 (human)

A lys-63-specific deubiquitinase BRCC36 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P46736-3.


E3 ubiquitin-protein ligase TRIP12 isoform h4 (human)

An E3 ubiquitin-protein ligase TRIP12 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q14669-4.


receptor-type tyrosine-protein kinase FLT3 isoform h2 (human)

A receptor-type tyrosine-protein kinase FLT3 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P36888-2.


receptor-type tyrosine-protein kinase FLT3

A CSF-1/PDGF receptor-type tyrosine-protein kinase that is a translation product of the human FLT3 gene or a 1:1 ortholog thereof.


receptor-type tyrosine-protein kinase FLT3, signal peptide removed form (human)

A receptor-type tyrosine-protein kinase FLT3 (human) that has had the signal peptide removed. UniProtKB:P36888, 27-993.


receptor-type tyrosine-protein kinase FLT3 isoform h1 (human)

A receptor-type tyrosine-protein kinase FLT3 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P36888-1.


very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 1 isoform h2 (human)

A very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:B0YJ81-2.


smad2 isoform Long phosphorylated 4 (human)

A smad2 isoform Long phosphorylated 4 in human. This form is phosphorylated at the clusters of [S/T]P motifs within the MH1-MH2 domain linker region. UniProtKB:Q15796-1, Thr-220, MOD:00047|Ser-245/Ser-250/Ser-255, MOD:00046.


retinol dehydrogenase 10 isoform 1 (human)

A retinol dehydrogenase 10 isoform 1 that is encoded in the genome of human.


Triple-Class Refractory Plasma Cell Myeloma

Plasma cell myeloma that is resistant to three classes of therapeutic agents, including proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies.


aspartate aminotransferase, mitochondrial, transit peptide removed pyridoxal phosphate lysine 1 (human)

An aspartate aminotransferase, mitochondrial (human) that has had the transit peptide removed and has been post-translationally modified to include pyridoxal phosphate lysine at position 279 of the amino acid sequence represented by UniProtKB:P00505. UniProtKB:P00505, 30-430, Lys-279, MOD:00128.


hydroxycarboxylic acid receptor 2

A hydroxycarboxylic acid receptor protein that is a translation product of the human HCAR2 gene or a 1:1 ortholog thereof.


A protein that is a translation product of the human MTHFR gene or a 1:1 ortholog thereof.


methylenetetrahydrofolate reductase (NADPH) isoform h2 (human)

A methylenetetrahydrofolate reductase (NADPH) (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P42898-2.


methylenetetrahydrofolate reductase (NADPH) isoform h1 (human)

A methylenetetrahydrofolate reductase (NADPH) (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P42898-1.


proton-coupled zinc antiporter SLC30A5 isoform h2 (human)

A proton-coupled zinc antiporter SLC30A5 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q8TAD4-2.


P protein isoform h3 (human)

A P protein (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q04671-3.


TGF-beta receptor type-1, signal peptide removed ubiquitinated form (human)

A TGF-beta receptor type-1 (human) that has had the signal peptide removed and that includes at least one ubiquitinated lysine. UniProtKB:P36897, 34-503, MOD:01148.


phospholipase DDHD1 isoform h3 (human)

A phospholipase DDHD1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q8NEL9-3.


mitochondrial basic amino acids transporter isoform 1 (mouse)

A mitochondrial basic amino acids transporter isoform 1 that is encoded in the genome of mouse.


hemopexin O-glycosylated 11 (human)

A hemopexin (human) that has been O-glycosylated at the residue equivalent to Thr-29 of the amino acid sequence represented by UniProtKB:P02790-1, in which the glycan composition is represented by GlyTouCan:G58001LT. Example: UniProtKB:P02790-1, Thr-29, MOD:00005~GNO:G58001LT.


mitogen-activated protein kinase 7 isoform h2 (human)

A mitogen-activated protein kinase 7 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q13164-2.


mitogen-activated protein kinase 7

A protein that is a translation product of the human MAPK7 gene or a 1:1 ortholog thereof.


mitogen-activated protein kinase 7 isoform h3 (human)

A mitogen-activated protein kinase 7 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q13164-3.


mitogen-activated protein kinase 7, initiator methionine removed form (human)

A mitogen-activated protein kinase 7 (human) that has had the initiator methionine removed. UniProtKB:Q13164, 2-816.


mitogen-activated protein kinase 7, initiator methionine removed phosphorylated 2 (human)

A mitogen-activated protein kinase 7 (human) that has had the initiator methionine removed and has been post-translationally modified to include phosphothreonine at position 219, and phosphotyrosine at position 221 of the amino acid sequence represented by UniProtKB:Q13164. UniProtKB:Q13164, 2-816, Thr-219, MOD:00047|Tyr-221, MOD:00048.


mitogen-activated protein kinase 7 isoform 1 phosphorylated 1 (human)

A mitogen-activated protein kinase 7 isoform 1 phosphorylated 1 in human. UniProtKB:Q13164-1, Thr-28/Thr-219/Thr-733, MOD:00047|Tyr-221, MOD:00048|Ser-421/Ser-433/Ser-496/Ser-731, MOD:00046.


mitogen-activated protein kinase 7 isoform h4 (human)

A mitogen-activated protein kinase 7 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q13164-4.


mitogen-activated protein kinase 7 isoform 1 (human)

A mitogen-activated protein kinase 7 isoform 1 that is encoded in the genome of human.


heat shock protein HSP 90-alpha isoform 1 (human)

A heat shock protein HSP 90-alpha (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P07900-1.


cftr isoform 1 phosphorylated 2 (human)

A cftr isoform 1 phosphorylated 2 in human. Example: UniProtKB:P13569-1, Ser-686/Ser-737/Ser-768/Ser-790/Ser-795/Ser-813, MOD:00046.


maleylacetoacetate isomerase isoform h3 (human)

A maleylacetoacetate isomerase (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:O43708-3.


maleylacetoacetate isomerase isoform h1 (human)

A maleylacetoacetate isomerase (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:O43708-1.


maleylacetoacetate isomerase isoform h2 (human)

A maleylacetoacetate isomerase (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:O43708-2.


cytochrome P450 3A7 isoform h1 (human)

A cytochrome P450 3A7 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P24462-1.


cytochrome P450 3A7 isoform h2 (human)

A cytochrome P450 3A7 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P24462-2.


serum paraoxonase/arylesterase 1 N-glycosylated 9 (human)

A serum paraoxonase/arylesterase 1 (human) that has been N-glycosylated at the residue equivalent to Asn-253 of the amino acid sequence represented by UniProtKB:P27169-1, in which the glycan composition is represented by GlyTouCan:G95865ZB. Example: UniProtKB:P27169-1, Asn-253, MOD:00160~GNO:G95865ZB.


kallikrein-6 N-glycosylated 4 (human)

A kallikrein-6 (human) that has been N-glycosylated at the residue equivalent to Asn-134 of the amino acid sequence represented by UniProtKB:Q92876-1, in which the glycan structure is represented by GlyTouCan:G08146BT. Example: UniProtKB:Q92876-1, Asn-134, MOD:00160~GNO:G08146BT.


kallikrein-6 isoform h3 (human)

A kallikrein-6 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q92876-3.


kallikrein-6 N-glycosylated 12 (human)

A kallikrein-6 (human) that has been N-glycosylated at the residue equivalent to Asn-134 of the amino acid sequence represented by UniProtKB:Q92876-1, in which the glycan structure is represented by GlyTouCan:G56069TX. Example: UniProtKB:Q92876-1, Asn-134, MOD:00160~GNO:G56069TX.


kallikrein-6 N-glycosylated 13 (human)

A kallikrein-6 (human) that has been N-glycosylated at the residue equivalent to Asn-134 of the amino acid sequence represented by UniProtKB:Q92876-1, in which the glycan structure is represented by GlyTouCan:G57818FI. Example: UniProtKB:Q92876-1, Asn-134, MOD:00160~GNO:G57818FI.


kallikrein-6 N-glycosylated 15 (human)

A kallikrein-6 (human) that has been N-glycosylated at the residue equivalent to Asn-134 of the amino acid sequence represented by UniProtKB:Q92876-1, in which the glycan structure is represented by GlyTouCan:G92534LG. Example: UniProtKB:Q92876-1, Asn-134, MOD:00160~GNO:G92534LG.


kallikrein-6 N-glycosylated 11 (human)

A kallikrein-6 (human) that has been N-glycosylated at the residue equivalent to Asn-134 of the amino acid sequence represented by UniProtKB:Q92876-1, in which the glycan structure is represented by GlyTouCan:G53965RU. Example: UniProtKB:Q92876-1, Asn-134, MOD:00160~GNO:G53965RU.


kallikrein-6 N-glycosylated 6 (human)

A kallikrein-6 (human) that has been N-glycosylated at the residue equivalent to Asn-134 of the amino acid sequence represented by UniProtKB:Q92876-1, in which the glycan structure is represented by GlyTouCan:G21327TO. Example: UniProtKB:Q92876-1, Asn-134, MOD:00160~GNO:G21327TO.


kallikrein-6 N-glycosylated 3 (human)

A kallikrein-6 (human) that has been N-glycosylated at the residue equivalent to Asn-134 of the amino acid sequence represented by UniProtKB:Q92876-1, in which the glycan structure is represented by GlyTouCan:G07493GF. Example: UniProtKB:Q92876-1, Asn-134, MOD:00160~GNO:G07493GF.


kallikrein-6 N-glycosylated 5 (human)

A kallikrein-6 (human) that has been N-glycosylated at the residue equivalent to Asn-134 of the amino acid sequence represented by UniProtKB:Q92876-1, in which the glycan structure is represented by GlyTouCan:G15828HX. Example: UniProtKB:Q92876-1, Asn-134, MOD:00160~GNO:G15828HX.


kallikrein-6 N-glycosylated 8 (human)

A kallikrein-6 (human) that has been N-glycosylated at the residue equivalent to Asn-134 of the amino acid sequence represented by UniProtKB:Q92876-1, in which the glycan structure is represented by GlyTouCan:G28536BG. Example: UniProtKB:Q92876-1, Asn-134, MOD:00160~GNO:G28536BG.


kallikrein-6 N-glycosylated 7 (human)

A kallikrein-6 (human) that has been N-glycosylated at the residue equivalent to Asn-134 of the amino acid sequence represented by UniProtKB:Q92876-1, in which the glycan structure is represented by GlyTouCan:G22208HN. Example: UniProtKB:Q92876-1, Asn-134, MOD:00160~GNO:G22208HN.


kallikrein-6 N-glycosylated 1 (human)

A kallikrein-6 (human) that has been N-glycosylated at the residue equivalent to Asn-134 of the amino acid sequence represented by UniProtKB:Q92876-1, in which the glycan structure is represented by GlyTouCan:G01659NO. Example: UniProtKB:Q92876-1, Asn-134, MOD:00160~GNO:G01659NO.


kallikrein-6 N-glycosylated 10 (human)

A kallikrein-6 (human) that has been N-glycosylated at the residue equivalent to Asn-134 of the amino acid sequence represented by UniProtKB:Q92876-1, in which the glycan structure is represented by GlyTouCan:G45495MK. Example: UniProtKB:Q92876-1, Asn-134, MOD:00160~GNO:G45495MK.


kallikrein-6 N-glycosylated 9 (human)

A kallikrein-6 (human) that has been N-glycosylated at the residue equivalent to Asn-134 of the amino acid sequence represented by UniProtKB:Q92876-1, in which the glycan structure is represented by GlyTouCan:G44369QM. Example: UniProtKB:Q92876-1, Asn-134, MOD:00160~GNO:G44369QM.


kallikrein-6 N-glycosylated 2 (human)

A kallikrein-6 (human) that has been N-glycosylated at the residue equivalent to Asn-134 of the amino acid sequence represented by UniProtKB:Q92876-1, in which the glycan structure is represented by GlyTouCan:G03081ER. Example: UniProtKB:Q92876-1, Asn-134, MOD:00160~GNO:G03081ER.


kallikrein-6 isoform h1 (human)

A kallikrein-6 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q92876-1.


kallikrein-6 isoform h2 (human)

A kallikrein-6 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q92876-2.


kallikrein-6 N-glycosylated 14 (human)

A kallikrein-6 (human) that has been N-glycosylated at the residue equivalent to Asn-134 of the amino acid sequence represented by UniProtKB:Q92876-1, in which the glycan structure is represented by GlyTouCan:G68969GZ. Example: UniProtKB:Q92876-1, Asn-134, MOD:00160~GNO:G68969GZ.


poly(A) RNA polymerase, mitochondrial isoform h2 (human)

A poly(A) RNA polymerase, mitochondrial (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9NVV4-2.


activated factor Xa heavy chain (human)

An activated factor Xa heavy chain in human. UniProtKB:P00742, 235-488.


elongation factor 1-delta isoform 3 (human)

An elongation factor 1-delta isoform 3 that is encoded in the genome of human.


thymidine phosphorylase isoform h2 (human)

A thymidine phosphorylase (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P19971-2.


THO complex subunit 5 homolog isoform 1 (human)

A THO complex subunit 5 isoform 1 that is encoded in the genome of human.


THO complex subunit 5 homolog, initiator methionine removed form (human)

A THO complex subunit 5 homolog (human) that has had the initiator methionine removed. UniProtKB:Q13769, 2-683.


THO complex subunit 5 homolog phosphorylated 1 (human)

A THO complex subunit 5 homolog (human) that has been phosphorylated at Tyr-225. UniProtKB:Q13769, Tyr-225, MOD:00048.


chondroitin sulfate synthase 3 O-glycosylated 2 (human)

A chondroitin sulfate synthase 3 (human) that has been O-glycosylated at the residue equivalent to Thr-122 of the amino acid sequence represented by UniProtKB:Q70JA7-1, in which the glycan composition is represented by GlyTouCan:G43417UB. Example: UniProtKB:Q70JA7-1, Thr-122, MOD:00005~GNO:G43417UB.


serine/threonine-protein kinase N3 phosphorylated 1 (human)

A serine/threonine-protein kinase N3 (human) that has been phosphorylated on the residue at the position equivalent to Thr-718 of the amino acid sequence represented by UniProtKB:Q6P5Z2. UniProtKB:Q6P5Z2, Thr-718, MOD:00047.


dapper homolog 2 isoform h2 (human)

A dapper homolog 2 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q5SW24-2.


iodotyrosine deiodinase 1 isoform h1 (human)

An iodotyrosine deiodinase 1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q6PHW0-1.


sulfite oxidase, mitochondrial, transit peptide removed form (human)

A sulfite oxidase, mitochondrial (human) that has had the transit peptide removed. UniProtKB:P51687, 80-545.


tissue-type plasminogen activator N-glycosylated 16 (human)

A tissue-type plasminogen activator (human) that has been N-glycosylated at the residue equivalent to Asn-152 of the amino acid sequence represented by UniProtKB:P00750-1, in which the glycan structure is represented by GlyTouCan:G77038WW. Example: UniProtKB:P00750-1, Asn-152, MOD:00160~GNO:G77038WW.


Ral guanine nucleotide dissociation stimulator-like 1 isoform B (human)

A Ral guanine nucleotide dissociation stimulator-like 1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9NZL6-2.


Ral guanine nucleotide dissociation stimulator-like 1 isoform A (human)

A Ral guanine nucleotide dissociation stimulator-like 1 isoform 1 that is encoded in the genome of human.


extracellular matrix organizing protein FRAS1 isoform h5 (human)

An extracellular matrix organizing protein FRAS1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q86XX4-5.


BRISC complex subunit Abraxas 2 isoform 1 (human)

A BRISC complex subunit Abraxas 2 isoform 1 that is encoded in the genome of human.


BRISC complex subunit Abro1 isoform 1 (mouse)

A BRISC complex subunit Abraxas 2 isoform 1 that is encoded in the genome of mouse.


aminodiol

An amino alcohol having two hydroxy functional groups.


A 2-aminooctadecene-1,3-diol having its double bond at position 4.


An aminodiol composed of any octadecene having hydroxy functional groups at positions 1 and 3 and an amino substituent at position 2.


sphingenine

A 2-aminooctadecene-1,3-diol having (2S,3R)-configuration.


CID 31270

A sphingenine in which the C=C double bond is located at the 4-position.


An aminodiol that is octadecane bearing two hydroxy substituents at positions 1 and 3 as well as an amino substituent at position 2.


corrinoid adenosyltransferase MMAB

A protein that is a translation product of the human MMAB gene or a 1:1 ortholog thereof.


corrinoid adenosyltransferase MMAB, transit peptide removed form (human)

A corrinoid adenosyltransferase MMAB (human) that has had the transit peptide removed. UniProtKB:Q96EY8, 33-250.


5-hydroxytryptamine receptor 2A isoform h2 (human)

A 5-hydroxytryptamine receptor 2A (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P28223-2.


haptoglobin N-glycosylated 8 (human)

A haptoglobin (human) that has been N-glycosylated at the residue equivalent to Asn-184 of the amino acid sequence represented by UniProtKB:P00738-1, in which the glycan structure is represented by GlyTouCan:G31118FR. Example: UniProtKB:P00738-1, Asn-184, MOD:00160~GNO:G31118FR.


Breast Carcinoma Metastatic in the Lung

A carcinoma that arises from the breast and has metastasized to the lung.


arenesulfonic acid

Organic derivatives of sulfonic acid in which the sulfo group is linked directly to carbon of an aryl group.


coagulation factor X N-glycosylated 2 (human)

A coagulation factor X (human) that has been N-glycosylated at the residue equivalent to Asn-221 of the amino acid sequence represented by UniProtKB:P00742-1, in which the glycan structure is represented by GlyTouCan:G24501HF. Example: UniProtKB:P00742-1, Asn-221, MOD:00160~GNO:G24501HF.


interferon gamma isoform 1, signal peptide removed N-glycosylated 1 (human)

An interferon gamma isoform 1, signal peptide removed glycosylated form in human in which N-linked glycosylation occurs at Asn-48 and Asn-120. UniProtKB:P01579-1, 24-157, Asn-48/Asn-120, MOD:00160.


phosphatidylinositol N-acetylglucosaminyltransferase subunit Y isoform 1 (human)

A phosphatidylinositol N-acetylglucosaminyltransferase subunit Y isoform 1 that is encoded in the genome of human.


integrin beta-7 isoform 1 (human)

An integrin beta-7 isoform 1 that is encoded in the genome of human.


integrin beta-7 isoform Short (human)

An integrin beta-7 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P26010-2.


integrin beta-7 isoform 1, signal peptide removed form (human)

An integrin beta-7 isoform 1, signal peptide removed form in human. UniProtKB:P26010-1, 20-798.


serine incorporator 1

A protein that is a translation product of the human SERINC1 gene or a 1:1 ortholog thereof.


serine incorporator 1 isoform 1 (human)

A serine incorporator 1 isoform 1 that is encoded in the genome of human.


RAF proto-oncogene serine/threonine-protein kinase isoform 1 phosphorylated 3 (human)

A RAF proto-oncogene serine/threonine-protein kinase isoform 1 phosphorylated 3 in human. UniProtKB:P04049-1, Ser-259/Ser-621, MOD:00046.


RAF proto-oncogene serine/threonine-protein kinase isoform 1 (human)

A RAF proto-oncogene serine/threonine-protein kinase isoform 1 that is encoded in the genome of human.


RAF proto-oncogene serine/threonine-protein kinase isoform 1 phosphorylated 2 (human)

A RAF proto-oncogene serine/threonine-protein kinase isoform 1 phosphorylated 2 in human. UniProtKB:P04049-1, Ser-338/Ser-339, MOD:00046.


RAS guanyl-releasing protein 1 isoform h2 (human)

A RAS guanyl-releasing protein 1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:O95267-2.


DNA repair protein complementing XP-C cells isoform h2 (human)

A DNA repair protein complementing XP-C cells (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q01831-2.


versican core protein O-glycosylated 117 (human)

A versican core protein (human) that has been O-glycosylated at the residue equivalent to Thr-1569 of the amino acid sequence represented by UniProtKB:P13611-1, in which the glycan composition is represented by GlyTouCan:G43417UB. Example: UniProtKB:P13611-1, Thr-1569, MOD:00005~GNO:G43417UB.


L-threo-isocitric acid

The (1S,2R)-stereoisomer of isocitric acid.


A 1,2-diacyl-sn-glycerol in which the 1-acyl group is specified as oleoyl.


2-acylglycerol 22:4

A 2-monoglyceride in which the acyl group contains 22 carbons and 4 double bonds.


monoacylglycerol 22:4

A monoglyceride in which the acyl groups contain a total of 22 carbons and 4 double bonds


1-acylglycerol 22:4

A 1-monoglyceride in which the acyl group contains 22 carbons and 4 double bonds.


immunoglobulin heavy constant mu N-glycosylated 70 (human)

An immunoglobulin heavy constant mu (human) that has been N-glycosylated at the residue equivalent to Asn-440 of the amino acid sequence represented by UniProtKB:P01871-1, in which the glycan composition is represented by GlyTouCan:G41247ZX. Example: UniProtKB:P01871-1, Asn-440, MOD:00160~GNO:G41247ZX.


versican core protein O-glycosylated 219 (human)

A versican core protein (human) that has been O-glycosylated at the residue equivalent to Thr-2887 of the amino acid sequence represented by UniProtKB:P13611-1, in which the glycan composition is represented by GlyTouCan:G43417UB. Example: UniProtKB:P13611-1, Thr-2887, MOD:00005~GNO:G43417UB.


low-density lipoprotein receptor, signal peptide removed form (human)

A low-density lipoprotein receptor (human) that has had the signal peptide removed. UniProtKB:P01130, 22-860.


TGF-beta receptor type-2 sequence variant N435S (human)

A TGF-beta receptor type-2 (human) that has a Ser residue at the position equivalent to Asn-435 of the amino acid sequence represented by UniProtKB:P37173-1. Example: UniProtKB:P37173-1, Asn-435, CHEBI:29999.


diacylglycerol kinase delta isoform h2 (human)

A diacylglycerol kinase delta (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q16760-1.


sodium-dependent neutral amino acid transporter B(0)AT1 isoform 1 (human)

A sodium-dependent neutral amino acid transporter B(0)AT1 isoform 1 that is encoded in the genome of human.


immunoglobulin heavy constant mu N-glycosylated 30 (human)

An immunoglobulin heavy constant mu (human) that has been N-glycosylated at the residue equivalent to Asn-272 of the amino acid sequence represented by UniProtKB:P01871-1, in which the glycan composition is represented by GlyTouCan:G12580WI. Example: UniProtKB:P01871-1, Asn-272, MOD:00160~GNO:G12580WI.


phosphopentomutase isoform h1 (human)

A phosphopentomutase (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q96G03-1.


proto-oncogene tyrosine-protein kinase Src phosphorylated 1 (human)

A proto-oncogene tyrosine-protein kinase Src (human) that has been phosphorylated on the residue at the position equivalent to Ser-75 of the amino acid sequence represented by UniProtKB:P12931-1. Example: UniProtKB:P12931-1, Ser-75, MOD:00046.


protein-lysine 6-oxidase N-glycosylated 1 (human)

A protein-lysine 6-oxidase (human) that has been N-glycosylated at the residue equivalent to Asn-144 of the amino acid sequence represented by UniProtKB:P28300-1, in which the glycan composition is represented by GlyTouCan:G92050GC. Example: UniProtKB:P28300-1, Asn-144, MOD:00160~GNO:G92050GC.


ubiquitin carboxyl-terminal hydrolase 5 isoform Long (human)

A ubiquitin carboxyl-terminal hydrolase 5 isoform 1 that is encoded in the genome of human.


N-alpha-acetyltransferase 60

A protein that is a translation product of the human NAA60 gene or a 1:1 ortholog thereof.


N-alpha-acetyltransferase 60 isoform 1 (human)

An N-alpha-acetyltransferase 60 isoform 1 that is encoded in the genome of human.


N-alpha-acetyltransferase 60 isoform h5 (human)

An N-alpha-acetyltransferase 60 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9H7X0-5.


N-alpha-acetyltransferase 60 isoform h4 (human)

An N-alpha-acetyltransferase 60 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9H7X0-4.


N-alpha-acetyltransferase 60 isoform h2 (human)

An N-alpha-acetyltransferase 60 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9H7X0-2.


N-alpha-acetyltransferase 60 isoform h3 (human)

An N-alpha-acetyltransferase 60 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9H7X0-3.


prosaposin N-glycosylated 6 (human)

A prosaposin (human) that has been N-glycosylated at the residue equivalent to Asn-101 of the amino acid sequence represented by UniProtKB:P07602-1, in which the glycan composition is represented by GlyTouCan:G27622TD. Example: UniProtKB:P07602-1, Asn-101, MOD:00160~GNO:G27622TD.


urocanate hydratase isoform 1 (human)

A urocanate hydratase isoform 1 that is encoded in the genome of human.


urocanate hydratase isoform h2 (human)

A urocanate hydratase (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q96N76-2.


histone H2A type 2-B, initiator methionine removed asymmetrically-dimethylated 2 (human)

A histone H2A type 2-B (human) that has had the initiator methionine removed and has been post-translationally modified to include asymmetric dimethyl-L-arginine at position 12 of the amino acid sequence represented by UniProtKB:Q8IUE6. UniProtKB:Q8IUE6, 2-130, Arg-12, MOD:00077.


histone H2A type 2-A, initiator methionine removed dimethylated 1 (human)

A histone H2A type 2-A (human) that has had the initiator methionine removed and that has been dimethylated at the position equivalent to Arg-4 of the amino acid sequence represented by UniProtKB:Q6FI13. UniProtKB:Q6FI13, 2-130, Arg-4, MOD:00783.


Stage IIA Lung Small Cell Carcinoma AJCC v7

Stage IIA includes: (T2b, N0, M0); (T1a, N1, M0); (T1b, N1, M0); (T2a, N1, M0).  T2b: Lung cancer with a tumor size more than 5 cm but 7 cm or less in greatest dimension.  T1a: Lung cancer with a tumor size of 2 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  N0: No regional lymph node metastasis.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 7th ed.)


neoplasm of thorax

A neoplasm (disease) that involves the thoracic segment of trunk.


Stage IVB Lung Cancer AJCC v8

Stage IVB includes: Any T, Any N, M1c. M1c: Tumor with multiple extrathoracic metastases in a single organ or in multiple organs. (AJCC 8th ed.)


Advanced Bronchogenic Carcinoma

Bronchogenic carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Lung squamous cell carcinoma stage I

Stage I includes: IA: (T1a, N0, M0); (T1b, N0, M0) and IB: (T2a, N0, M0).  T1a: Lung cancer with a tumor size of 2 cm or less n greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Stage IIA Lung Squamous Cell Carcinoma AJCC v7


Lung Adenocarcinoma by AJCC v7 Stage

A term that refers to the staging of lung adenocarcinoma, following the rules of the TNM AJCC v7 classification system.


Lung Secretory Carcinoma

A rare carcinoma that arises from the lung and has histopathological, immunohistochemical, and genetic features identical to those described in breast and salivary gland secretory carcinomas.


Stage IA Lung Small Cell Carcinoma AJCC v7

Stage IA includes: (T1a, N0, M0); (T1b, N0, M0).  T1a: Lung cancer with a tumor size of 2 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Small cell lung cancer limited stage

Small cell lung carcinoma which is confined to one hemi-thorax and the regional lymph nodes.


neuroendocrine carcinoma of lung

A high grade malignant neoplasm that arises from the lung and is characterized by the presence of malignant neuroendocrine cells.  This category includes small cell lung carcinoma, large cell lung neuroendocrine carcinoma, and combined lung carcinoma.


Non-small cell lung cancer stage IIIB

Stage IIIB includes: (T1a, N3, M0); (T1b, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N3, M0); (T4, N2, M0); (T4, N3, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  N3: Lung cancer with metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Metastatic non-small cell lung cancer

Stage IV includes: (Any T, Any N, M1a); (Any T, Any N, M1b).  M1a: Lung cancer with separate tumor nodule(s) in a contralateral lobe; tumor with pleural nodules or malignant pleural (or pericardial) effusion.  M1b: Distant metastasis. (AJCC 7th ed.)


Stage IIIA Lung Squamous Cell Carcinoma AJCC v7

Stage IIIA includes: (T1a, N2, M0); (T1b, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T3, N2, M0); (T4, N0, M0); (T4, N1, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Stage I Lung Cancer AJCC v8

Stage I includes: IA1: (T1mi, N0, M0); (T1a, N0, M0); IA2: (T1b, N0, M0); IA3: (T1c, N0, M0); IB: (T2a, N0, M0). T1mi: Minimally invasive adenocarcinoma: adenocarcinoma (3 cm or less in greatest dimension) with a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension. T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)


Advanced Lung Adenosquamous Carcinoma

Lung adenosquamous carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Lung Micropapillary Adenocarcinoma

An aggressive variant of lung adenocarcinoma that exhibits a micropapillary architectural pattern. The prognosis is usually poor.


Invasive Lung Mucinous Adenocarcinoma

An invasive adenocarcinoma that arises from the lung. It is characterized by the presence of tall columnar cells and mucin production. This category refers to cases formerly classified as mucinous bronchioloalveolar carcinoma, excluding cases that meet the criteria for adenocarcinoma in situ or mucinous minimally invasive adenocarcinoma.


Lung Spindle Cell Carcinoma

A morphologic variant of sarcomatoid carcinoma characterized by the presence of malignant spindle cells and focal lymphoplasmacytic infiltrates.  Adenocarcinoma cells, malignant squamous cells, and giant cells are not present.


Locally Advanced Lung Non-Small Cell Carcinoma

A non-small cell carcinoma of the lung that has spread from its original site of growth to nearby tissues or lymph nodes.


Stage 0 Non-Small Cell Lung Cancer AJCC v6 and v7

Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Occult Lung Cancer AJCC v8

Occult lung cancer includes: TX, N0, M0. TX: Primary tumor cannot be assessed. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Refractory Lung Squamous Cell Carcinoma

Lung squamous cell carcinoma that is resistant to treatment.


Childhood Lung Small Cell Carcinoma

A rare small cell carcinoma of the lung that occurs during childhood.


Invasive Lung Non-Mucinous Adenocarcinoma

An invasive adenocarcinoma that arises from the lung. It is characterized by the absence of tall columnar cells and mucin production. This category includes lepidic adenocarcinoma, acinar adenocarcinoma, papillary adenocarcinoma, micropapillary adenocarcinoma, and solid adenocarcinoma.


Refractory Lung Non-Small Cell Squamous Carcinoma

Lung non-small cell squamous carcinoma that is resistant to treatment.


Lung Carcinoma Metastatic in the Brain

A carcinoma that has spread to the brain from its original site in the lung, through the hematogenous route.


Stage IIIC Lung Cancer AJCC v8

Stage IIIC includes: (T3, N3, M0); (T4, N3, M0). T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. T4: Tumor measuring more than 7 cm or tumor of any size invading one or more of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina; separate tumor nodule(s) in an ipsilateral lobe different from that of the primary. N3: Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s). M0: No distant metastasis. (AJCC 8th ed.)


Advanced Lung Neuroendocrine Neoplasm

A lung neuroendocrine neoplasm that has spread extensively to other anatomic sites or is no longer responding to treatment.


Metastatic Lung Small Cell Carcinoma

A small cell carcinoma that arises from the lung and has metastasized to another anatomic site.


Refractory Extensive Stage Lung Small Cell Carcinoma

Extensive stage small cell lung carcinoma that does not respond to treatment.


Stage 0 Squamous Cell Lung Carcinoma AJCC v6 and v7


Unresectable Lung Non-Small Cell Squamous Carcinoma

Lung non-small cell squamous carcinoma that is not amenable to surgical resection.


Non-small cell lung cancer stage III

Stage III includes: IIIA (T1a, N2, M0); (T1b, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T3, N2, M0); (T4, N0, M0); (T4, N1, M0) and IIIB (T1a, N3, M0); (T1b, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N3, M0); (T4, N2, M0); (T4, N3, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  N3: Lung cancer with metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Occult Lung Carcinoma

A lung carcinoma detectable by sputum cytology or bronchial washings only.  The primary tumor is undetectable radiographically or during bronchoscopy; therefore, it can not be assessed.


Platinum-Resistant Lung Small Cell Carcinoma

Lung small cell carcinoma that is resistant to platinum therapy.


Lung Squamous Cell Carcinoma, Small Cell Variant

A poorly differentiated morphologic variant of squamous cell lung carcinoma characterized by the presence of small tumor cells with focal squamous differentiation.


Lung squamous cell carcinoma metastatic

A squamous cell carcinoma that arises from the lung and has metastasized to another anatomic site.


Lung Non-Keratinizing Squamous Cell Carcinoma

A squamous cell lung carcinoma characterized by the absence of keratinization, pearl formation, and intercellular bridges.


Stage IIIB Lung Cancer AJCC v8

Stage IIIB includes: (T1a, N3, M0); (T1b, N3, M0); (T1c, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N2, M0); (T4, N2, M0). T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension. T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. T4: Tumor measuring more than 7 cm or tumor of any size invading one or more of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina; separate tumor nodule(s) in an ipsilateral lobe different from that of the primary. N2: Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s). N3: Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s). M0: No distant metastasis. (AJCC 8th ed.)


Stage IA Lung Squamous Cell Carcinoma AJCC v7

Stage IA includes: (T1a, N0, M0); (T1b, N0, M0).  T1a: Lung cancer with a tumor size of 2 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Solid Lung Adenocarcinoma

A morphologic variant of lung adenocarcinoma characterized by the presence of polygonal malignant cells forming sheets. Acinar, papillary, micropapillary, or lepidic growth patterns are absent.  If the tumor is 100 percent solid, intracellular mucin should be present in at least five tumor cells in each of two high-power fields and confirmed with mucin immunohistochemical stains. Tumors formerly classified as large cell carcinomas expressing pneumocyte immunohistochemical markers, even if intracellular mucin is absent, are now included in this category.


A morphologic variant of minimally invasive lung  adenocarcinoma characterized by the presence of Clara cells and/or type II cells.


Locally Advanced Lung Large Cell Neuroendocrine Carcinoma

Lung large cell neuroendocrine carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Stage IIB Non-Small Cell Lung Carcinoma AJCC v7

Stage IIB includes: (T2b, N1, M0); (T3, N0, M0).  T2b: Lung cancer with a tumor size more than 5 cm but 7 cm or less in greatest dimension.  T3: Lung cancer with a tumor size more than 7 cm or one that directly invades any of the following: parietal pleural (PL3) chest wall (including superior sulcus tumors), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumor in the main bronchus (less than 2 cm distal to the carina but without involvement of the carina); or associated atelectasis or obstructive pneumonitis of the entire lung or separate tumor nodule(s) in the same lobe. N0: No regional lymph node metastasis.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 7th ed.)


Lung Cancer by AJCC v7 Stage

A term that refers to the staging of lung carcinoma according to the American Joint Committee on Cancer, 7th edition.


Unresectable Lung Non-Small Cell Carcinoma

Lung non-small cell carcinoma that is not amenable to surgical resection.


Stage IIIA Lung Cancer AJCC v8

Stage IIIA includes: (T1a, N2, M0); (T1b, N2, M0); (T1c, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T4, N0, M0); (T4, N1, M0). T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension. T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. T4: Tumor measuring more than 7 cm or tumor of any size invading one or more of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina; separate tumor nodule(s) in an ipsilateral lobe different from that of the primary. N0: No regional lymph node metastases. N1: Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension. N2: Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s). M0: No distant metastasis. (AJCC 8th ed.)


Myoepithelial carcinoma of lung

A very rare malignant lung tumor with myoepithelial differentiation.


Unresectable Lung Carcinoid Tumor

Lung carcinoid tumor that is not amenable to surgical resection.


Resectable Lung Non-Small Cell Carcinoma

Lung non-small cell carcinoma that is amenable to surgical resection.


Occult Lung Adenosquamous Carcinoma

An adenosquamous lung carcinoma detectable by sputum cytology only.  The primary tumor is undetectable radiographically or during bronchoscopy; therefore, it can not be assessed.


Metastatic Lung Neuroendocrine Neoplasm

A neuroendocrine neoplasm that arises from the lung and has spread to another anatomic site.


Stage IIIB Lung Small Cell Carcinoma without Pleural Effusion AJCC v7

Stage IIIB small cell lung carcinoma that has not spread to the pleural fluid.


Epithelioid hemangioendothelioma of lung

A low-grade malignant blood vessel neoplasm arising from the lung.  It is characterized by the presence of epithelioid endothelial cells.  The neoplastic cells are arranged in cords and nests, which are embedded in a myxoid to hyalinized stroma.


Metastatic Lung Large Cell Neuroendocrine Carcinoma

Lung large cell neuroendocrine carcinoma that has spread from its original site of growth to another anatomic site.


Lung Non-Small Cell Cancer by AJCC v7 Stage

A term that refers to the staging of non-small cell lung carcinoma, following the rules of the TNM AJCC v7 classification system.


Stage IIIA Lung Cancer AJCC v7

Stage IIIA includes: (T1a, N2, M0); (T1b, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T3, N2, M0); (T4, N0, M0); (T4, N1, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Advanced Lung Non-Small Cell Carcinoma

Lung non-small cell carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Metastatic Lung Carcinoma

A carcinoma that arises from the lung and has metastasized to another anatomic site.


Advanced Lung Non-Small Cell Squamous Carcinoma

Non-small cell squamous lung carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Stage IIIA Lung Small Cell Carcinoma AJCC v7


Lung Osteosarcoma

A rare extraskeletal osteosarcoma that arises from the lung parenchyma.


Unresectable Lung Adenocarcinoma

Lung adenocarcinoma that is not amenable to surgical resection.


Stage 0 Lung Adenocarcinoma AJCC v6 and v7

Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage IB Lung Adenocarcinoma AJCC v7

Stage IB includes: T2a, N0, M0.  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Locally Advanced Lung Adenosquamous Carcinoma

Lung adenosquamous carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Stage IA1 Lung Cancer AJCC v8

Stage IA1 includes: IA1: (T1mi, N0, M0); (T1a, N0, M0). T1mi: Minimally invasive adenocarcinoma: adenocarcinoma (3 cm or less in greatest dimension) with a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension. T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)


Stage IB Lung Squamous Cell Carcinoma AJCC v7


Stage IVA Lung Cancer AJCC v8

Stage IVA includes: (Any T, Any N, M1a); (Any T, Any N, M1b). M1a: Tumor with separate tumor nodule(s) in a contralateral lobe; tumor with pleural or pericardial nodules or malignant pleural or pericardial effusion. Most pleural (pericardial) effusions with lung cancer are a result of the tumor. In a few patients, however, multiple microscopic examinations of pleural (pericardial) fluid are negative for tumor, and the fluid is nonbloody and not an exudate. If these elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging descriptor. M1b: Tumor with single extrathoracic metastasis in a single organ (including involvement of a single nonregional node). (AJCC 8th ed.)


Advanced Lung Large Cell Neuroendocrine Carcinoma

Lung large cell neuroendocrine carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Stage II Lung Small Cell Carcinoma AJCC v7

Stage II includes: IIA (T2b, N0, M0); (T1a, N1, M0); (T1b, N1, M0); (T2a, N1, M0) and IIB (T2b, N1, M0); (T3, N0, M0).  T2b: Lung cancer with a tumor size more than 5 cm but 7 cm or less in greatest dimension.  T1a: Lung cancer with a tumor size of 2 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  T3: Lung cancer with a tumor size more than 7 cm or one that directly invades any of the following: parietal pleural (PL3) chest wall (including superior sulcus tumors), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumor in the main bronchus (less than 2 cm distal to the carina but without involvement of the carina); or associated atelectasis or obstructive pneumonitis of the entire lung or separate tumor nodule(s) in the same lobe. N0: No regional lymph node metastasis.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 7th ed.)


Stage III Lung Cancer AJCC v7

Stage III includes: IIIA (T1a, N2, M0); (T1b, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T3, N2, M0); (T4, N0, M0); (T4, N1, M0) and IIIB (T1a, N3, M0); (T1b, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N3, M0); (T4, N2, M0); (T4, N3, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  N3: Lung cancer with metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Stage I Lung Cancer AJCC v7

Stage I includes: IA: (T1a, N0, M0); (T1b, N0, M0) and IB: (T2a, N0, M0).  T1a: Lung cancer with a tumor size of 2 cm or less n greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Lung Plasmacytoma

A plasmacytoma that arises in the lung.


Hodgkin's lymphoma of lung

A rare Hodgkin lymphoma that arises in and is confined to the lung at the time of diagnosis.


Stage IIB Lung Cancer AJCC v7

Stage IIB includes: (T2b, N1, M0); (T3, N0, M0).  T2b: Lung cancer with a tumor size more than 5 cm but 7 cm or less in greatest dimension.  T3: Lung cancer with a tumor size more than 7 cm or one that directly invades any of the following: parietal pleural (PL3) chest wall (including superior sulcus tumors), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumor in the main bronchus (less than 2 cm distal to the carina but without involvement of the carina); or associated atelectasis or obstructive pneumonitis of the entire lung or separate tumor nodule(s) in the same lobe. N0: No regional lymph node metastasis.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 7th ed.)


Stage IB Non-Small Cell Lung Carcinoma AJCC v7


Metastatic Lung Adenosquamous Carcinoma

An adenosquamous carcinoma that arises from the lung and has metastasized to another anatomic site.


Stage IB Lung Small Cell Carcinoma AJCC v7


Localized Lung Carcinoma

Lung carcinoma that is confined to the site in which it initially manifested without evidence of spread to other anatomic sites.


Refractory Lung Small Cell Carcinoma

Small cell lung carcinoma that does not respond to treatment.


Stage I Lung Cancer AJCC v6

Stage I includes: IA: (TI, N0, M0) and IB: (T2, N0, M0).  TI: Tumor 3 cm or less in greatest dimension surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus.  T2: Tumor with any of the following features of size or extent: More than 3cm in greatest dimension.  Involves main bronchus, 2cm or more distal to the carina.  Invades the visceral pleura.  N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 6th ed.)


Stage IA3 Lung Cancer AJCC v8

Stage IA3 includes: T1c, N0, M0. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)


Stage II Lung Cancer AJCC v8

Stage II includes: IIA: (T2b, N0, M0); IIB: (T1a, N1, M0); (T1b, N1, M0); (T1c, N1, M0); (T2a, N1, M0); (T2b, N1, M0); (T3, N0, M0). T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension.  T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension.  T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. N0: No regional lymph node metastases. N1: Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 8th ed.)


Unresectable Lung Carcinoma

Lung carcinoma that is not amenable to surgical resection.


Lung Hyalinizing Clear Cell Carcinoma

An extremely rare, low-grade carcinoma that arises endobronchially in the central airways. It is associated with the presence of EWSR1-ATF1 fusion gene and EWSR1-ATF1 fusion protein expression. It is composed of small to medium-sized malignant epithelial cells with clear and eosinophilic cytoplasm forming nests, cords, and trabeculae in a myxohyaline and fibrous stroma.


Stage IA Lung Non-Small Cell Carcinoma AJCC v7

Stage IA includes: (T1a, N0, M0); (T1b, N0, M0).  T1a: Lung cancer with a tumor size of 2 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Stage III Lung Cancer AJCC v6

Stage III includes: IIIA (T1, N2, M0); (T2, N2, M0); (T3, N1,M0); (T3, N2, M0) or IIIB (Any T, N3, M0); (T4, Any N, M0).  N1: Metastasis to ipsilateral peribronchial and/or ipsilateral hilar lymph nodes, and intrapulmonary nodes including involvement by direct extension of the primary tumor.  N2: Metastasis to ipsilateral mediastinal and/or subcarinal lymph node(s).  N3: Metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s).  T1: Tumor is 3 cm or less in greatest dimension, surrounded by lung or visceral pleura, and without bronchoscopic evidence of invasion more proximal than the lobar bronchus.  T2: Tumor has any of the following features of size or extent: more than 3 cm in greatest dimension; involves the main bronchus, 2 cm or more distal to the carina; invades the visceral pleura; associated with atelectasis or obstructive pneumonitis that extends to the hilar region but does not involve the entire lung.  T3: Tumor (of any size) directly invades any of the following: chest wall (including superior sulcus tumors), diaphragm, mediastinal pleura, parietal pericardium; or tumor in the main bronchus less than 2 cm distal to the carina but without involvement of the carina; or associated atelectasis or obstructive pneumonitis of the entire lung.  T4: Tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, esophagus, vertebral body, carina; or separate tumor nodules in the same lobe; or tumor with a malignant pleural effusion.  M0: No distant metastasis. (AJCC 6th ed.)


Refractory Lung Carcinoma

Lung carcinoma that does not respond to treatment.


Metastatic Carcinoma in the Lung

The spread of a carcinoma to the lung. This may be from a primary lung carcinoma, or from a carcinoma at a distant anatomic site.


Non-small cell lung cancer stage IIIA

Stage IIIA includes: (T1a, N2, M0); (T1b, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T3, N2, M0); (T4, N0, M0); (T4, N1, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Transplant-Related Lung Carcinoma

A lung carcinoma that arises in a patient with a history of organ transplantation.


Lung Cancer by AJCC v8 Stage

A term that refers to the staging of lung cancer, following the rules of the TNM AJCC v8 classification system. This staging system derives from analyses of the new retrospective and prospective databases of the International Association for the Study of Lung Cancer (IASLC). These databases contain information on patients diagnosed with lung cancer from 1999 to 2010 originating from 35 different databases in 16 countries around the world. This staging system applies to carcinomas of the lung, including non-small cell and small cell carcinomas, and bronchopulmonary carcinoid tumors. It does not apply to sarcomas or other rare tumors of the lung. (from AJCC 8th Ed.)


Lung Malignant PEComa

A malignant lung tumor that arises from perivascular epithelioid cells (PECs).


Adenocarcinoma of lung, stage III

Stage III includes: IIIA (T1a, N2, M0); (T1b, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T3, N2, M0); (T4, N0, M0); (T4, N1, M0) and IIIB (T1a, N3, M0); (T1b, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N3, M0); (T4, N2, M0); (T4, N3, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  N3: Lung cancer with metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Stage IIB Lung Cancer AJCC v8

Stage IIB includes: (T1a, N1, M0); (T1b, N1, M0); (T1c, N1, M0); (T2a, N1, M0); (T2b, N1, M0); (T3, N0, M0). T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension. T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. N0: No regional lymph node metastases. N1: Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 8th ed.)


Lung Small Cell Carcinoma by AJCC v7 Stage

A term that refers to the staging of small cell lung carcinoma, following the rules of the TNM AJCC v7 classification system.


thoracic cancer

A primary or metastatic malignant neoplasm affecting the tissues of the thorax.


Advanced Lung Non-Squamous Non-Small Cell Carcinoma

Non-squamous non-small cell lung carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma

Non-squamous non-small cell lung carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Colon Carcinoma Metastatic in the Lung

A carcinoma that originates from the colonic wall and has spread to the lungs.


Adenocarcinoma of lung, stage II

Stage II includes: IIA (T2b, N0, M0); (T1a, N1, M0); (T1b, N1, M0); (T2a, N1, M0) and IIB (T2b, N1, M0); (T3, N0, M0).  T2b: Lung cancer with a tumor size more than 5 cm but 7 cm or less in greatest dimension.  T1a: Lung cancer with a tumor size of 2 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  T3: Lung cancer with a tumor size more than 7 cm or one that directly invades any of the following: parietal pleural (PL3) chest wall (including superior sulcus tumors), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumor in the main bronchus (less than 2 cm distal to the carina but without involvement of the carina); or associated atelectasis or obstructive pneumonitis of the entire lung or separate tumor nodule(s) in the same lobe. N0: No regional lymph node metastasis.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 7th ed.)


Advanced Lung Carcinoma

A lung carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Stage III Lung Small Cell Carcinoma AJCC v7


Stage IV Lung Cancer AJCC v6

Stage IV includes: Any T, Any N, M1.  M1: Distant metastasis present. (AJCC 6th ed.)


Lung Squamous Cell Carcinoma In Situ

A preinvasive bronchial neoplastic lesion affecting the squamous epithelium. It is characterized by the absence of progression of maturation from base to luminal surface, basilar zone expansion with cellular crowding throughout the epithelium, absence of the intermediate zone, and surface flattening confined to the most superficial cells. The nuclear-to-cytoplasmic ratio is often high and variable, the chromatin is coarse and uneven, and mitotic figures are present through full thickness. The cell size may be markedly increased. Anisocytosis and pleomorphism may be present. (Adapted from WHO, 2015)


Stage IIA Lung Adenocarcinoma AJCC v7

Stage IIA includes: (T2b, N0, M0); (T1a, N1, M0); (T1b, N1, M0); (T2a, N1, M0).  T2b: Lung cancer with a tumor size more than 5 cm but 7 cm or less in greatest dimension.  T1a: Lung cancer with a tumor size of 2 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  N0: No regional lymph node metastasis.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 7th ed.)


Minimally Invasive Lung Mucinous Adenocarcinoma

A morphologic variant of minimally invasive lung adenocarcinoma characterized by tall columnar cells and mucin production.


Metastatic Lung Adenocarcinoma

Lung adenocarcinoma that has spread from its original site of growth to another anatomic site.


Unresectable Lung Non-Squamous Non-Small Cell Carcinoma

Lung non-squamous non-small cell carcinoma that is not amenable to surgical resection.


Unresectable Lung Large Cell Neuroendocrine Carcinoma

Lung large cell neuroendocrine carcinoma that is not amenable to surgical resection.


Locally Advanced Lung Neuroendocrine Neoplasm

A lung neuroendocrine neoplasm that has spread from its original site of growth to nearby tissues or lymph nodes.


keratinizing squamous cell carcinoma of lung

A squamous cell lung carcinoma characterized by the presence of keratinization, pearl formation, and/or intercellular bridges.


Lung Enteric Adenocarcinoma

A well-differentiated adenocarcinoma located in the lung periphery. It resembles colorectal adenocarcinoma with acinar and/or cribriform architecture and papillotubular structures.


Stage IIIB Lung Small Cell Carcinoma AJCC v7

Stage IIIB includes: (T1a, N3, M0); (T1b, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N3, M0); (T4, N2, M0); (T4, N3, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  N3: Lung cancer with metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Lung Melanoma

A rare malignant neoplasm that derives from melanocytes and arises from the lung in a patient with no history of previous melanoma and no evidence of melanoma in another site at the time of diagnosis.  It usually presents as a solitary lesion and the prognosis is poor.


Metastatic Lung Carcinoid Tumor

Lung carcinoid tumor that has spread from its original site of growth to another anatomic site.


Stage IV Lung Cancer AJCC v7

Stage IV includes: (Any T, Any N, M1a); (Any T, Any N, M1b).  M1a: Lung cancer with separate tumor nodule(s) in a contralateral lobe; tumor with pleural nodules or malignant pleural (or pericardial) effusion.  M1b: Distant metastasis. (AJCC 7th ed.)


Stage 0 Lung Cancer AJCC v8

Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ. Squamous cell carcinoma in situ (SCIS). Adenocarcinoma in situ (AIS): adenocarcinoma with pure lepidic pattern, 3 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Metastatic Lung Non-Squamous Non-Small Cell Carcinoma

A non-squamous non-small cell carcinoma that arises from the lung and has metastasized to another anatomic site.


Stage IV Lung Squamous Cell Carcinoma AJCC v7


Stage IIA Non-Small Cell Lung Carcinoma AJCC v7


Stage IB Lung Cancer AJCC v7

Stage IB includes: T2a, N0, M0.  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Locally Advanced Lung Carcinoma

A lung carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Small cell lung cancer extensive stage

Small cell lung carcinoma which has spread beyond one hemi-thorax and the regional lymph nodes.


Lung Squamous Cell Carcinoma, Papillary Variant

A morphologic variant of squamous cell lung carcinoma characterized by the presence of papillary structures.


Advanced Lung Squamous Cell Carcinoma

Lung squamous cell carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Oligometastatic Lung Carcinoma

Lung carcinoma that has metastasized to a limited number of sites.


Extramedullary Disease in Plasma Cell Myeloma Involving the Lung

Infiltration of the lung by malignant (clonal) plasma cells in patients with history of plasma cell myeloma.


Stage IIB Lung Small Cell Carcinoma AJCC v7

Stage IIB includes: (T2b, N1, M0); (T3, N0, M0).  T2b: Lung cancer with a tumor size more than 5 cm but 7 cm or less in greatest dimension.  T3: Lung cancer with a tumor size more than 7 cm or one that directly invades any of the following: parietal pleural (PL3) chest wall (including superior sulcus tumors), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumor in the main bronchus (less than 2 cm distal to the carina but without involvement of the carina); or associated atelectasis or obstructive pneumonitis of the entire lung or separate tumor nodule(s) in the same lobe. N0: No regional lymph node metastasis.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 7th ed.)


Lung Carcinoma Metastatic in the Liver

A carcinoma that originates from the lung and has spread to the liver.


Lung Squamous Cell Carcinoma by AJCC v7 Stage

A term that refers to the staging of squamous cell lung carcinoma, following the rules of the TNM AJCC v7 classification system.


Advanced Lung Carcinoid Tumor

Lung carcinoid tumor that has spread extensively to other anatomic sites or is no longer responding to treatment.


Platinum-Sensitive Lung Small Cell Carcinoma

Lung small cell carcinoma that is sensitive to platinum therapy.


logopenic progressive aphasia

Logopenic progressive aphasia (lv-PPA) is a form of primary progressive aphasia (PPA), characterized by impaired single-word retrieval and naming and impaired repetition with spared single-word comprehension and object knowledge.


Stage IIA Lung Cancer AJCC v8

Stage IIA includes: T2b, N0, M0. T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension.  N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)


Basaloid squamous cell carcinoma of lung

A morphologic variant of squamous cell lung carcinoma characterized by nuclear palisading.


Stage IV Lung Cancer AJCC v8

Stage IV includes: IVA: (Any T, Any N, M1a); (Any T, Any N, M1b); IVB: (Any T, Any N, M1c). M1a: Tumor with separate tumor nodule(s) in a contralateral lobe; tumor with pleural or pericardial nodules or malignant pleural or pericardial effusion. Most pleural (pericardial) effusions with lung cancer are a result of the tumor. In a few patients, however, multiple microscopic examinations of pleural (pericardial) fluid are negative for tumor, and the fluid is nonbloody and not an exudate. If these elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging descriptor. M1b: Tumor with single extrathoracic metastasis in a single organ (including involvement of a single nonregional node). M1c: Tumor with multiple extrathoracic metastases in a single organ or in multiple organs. (AJCC 8th ed.)


Colorectal Carcinoma Metastatic in the Lung

A carcinoma that originates from the wall of the colon or rectum and has spread to the lungs.


Stage IIIB Lung Squamous Cell Carcinoma AJCC v7

Stage IIIB includes: (T1a, N3, M0); (T1b, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N3, M0); (T4, N2, M0); (T4, N3, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  N3: Lung cancer with metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Pulmonary Artery Intimal Sarcoma

A sarcoma arising from the arterial intima of pulmonary arteries.


Advanced Lung Small Cell Carcinoma

Small cell lung carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Stage IB Lung Cancer AJCC v8

Stage IB includes: T2a, N0, M0. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)


Refractory Lung Non-Small Cell Carcinoma

Non-small cell lung carcinoma that does not respond to treatment.


Lung squamous cell carcinoma stage II

Stage II includes: IIA (T2b, N0, M0); (T1a, N1, M0); (T1b, N1, M0); (T2a, N1, M0) and IIB (T2b, N1, M0); (T3, N0, M0).  T2b: Lung cancer with a tumor size more than 5 cm but 7 cm or less in greatest dimension.  T1a: Lung cancer with a tumor size of 2 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  T3: Lung cancer with a tumor size more than 7 cm or one that directly invades any of the following: parietal pleural (PL3) chest wall (including superior sulcus tumors), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumor in the main bronchus (less than 2 cm distal to the carina but without involvement of the carina); or associated atelectasis or obstructive pneumonitis of the entire lung or separate tumor nodule(s) in the same lobe. N0: No regional lymph node metastasis.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 7th ed.)


Unresectable Lung Neuroendocrine Neoplasm

A lung neuroendocrine neoplasm that is not amenable to surgical resection.


Childhood Lung Non-Small Cell Carcinoma

A rare non-small cell carcinoma of the lung that occurs during childhood.


Locally Advanced Lung Adenocarcinoma

Lung adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Stage IIB Lung Squamous Cell Carcinoma AJCC v7

Stage IIB includes: (T2b, N1, M0); (T3, N0, M0).  T2b: Lung cancer with a tumor size more than 5 cm but 7 cm or less in greatest dimension.  T3: Lung cancer with a tumor size more than 7 cm or one that directly invades any of the following: parietal pleural (PL3) chest wall (including superior sulcus tumors), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumor in the main bronchus (less than 2 cm distal to the carina but without involvement of the carina); or associated atelectasis or obstructive pneumonitis of the entire lung or separate tumor nodule(s) in the same lobe. N0: No regional lymph node metastasis.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 7th ed.)


Prostate Carcinoma Metastatic in the Lung

A carcinoma that arises from the prostate gland and has spread to the lungs.


Refractory Lung Adenocarcinoma

Lung adenocarcinoma that is resistant to treatment.


Stage IA Lung Adenocarcinoma AJCC v7

Stage IA includes: (T1a, N0, M0); (T1b, N0, M0).  T1a: Lung cancer with a tumor size of 2 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Stage I Lung Small Cell Carcinoma AJCC v7

Stage I includes: IA: (T1a, N0, M0); (T1b, N0, M0) and IB: (T2a, N0, M0).  T1a: Lung cancer with a tumor size of 2 cm or less n greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Occult Lung Non-Small Cell Carcinoma

A non-small cell lung carcinoma detectable by sputum cytology only.  The primary tumor is undetectable radiographically or during bronchoscopy; therefore, it can not be assessed.


Stage IIIB Lung Small Cell Carcinoma with Pleural Effusion AJCC v7

Stage IIIB small cell lung carcinoma that has spread to the pleural fluid.


Secondary malignant neoplasm of lung

The spread of a malignant neoplasm to the lung. This may be from a primary lung malignant neoplasm, or from a malignant neoplasm at a distant site.


Non-mucinous adenocarcinoma in situ of lung

Lung adenocarcinoma in situ characterized by the presence of type II pneumocyte and/or Clara cell differentiation. Almost all cases of lung adenocarcinoma in situ are non-mucinous.


Lung Mucinous Adenocarcinoma In Situ

A very rare lung adenocarcinoma in situ variant characterized by the presence of tall columnar cells with basal nuclei and abundant cytoplasmic mucin.


Adenocarcinoma of lung, stage IV

Stage IV includes: (Any T, Any N, M1a); (Any T, Any N, M1b).  M1a: Lung cancer with separate tumor nodule(s) in a contralateral lobe; tumor with pleural nodules or malignant pleural (or pericardial) effusion.  M1b: Distant metastasis. (AJCC 7th ed.)


Metastatic Lung Non-Small Cell Carcinoma

A non-small cell carcinoma that arises from the lung and has metastasized to another anatomic site.


Combined Lung Small Cell Carcinoma and Lung Adenocarcinoma

A lung carcinoma characterized by a combination of small cell carcinoma and adenocarcinoma.


Lung squamous cell carcinoma stage III

Stage III includes: IIIA (T1a, N2, M0); (T1b, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T3, N2, M0); (T4, N0, M0); (T4, N1, M0) and IIIB (T1a, N3, M0); (T1b, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N3, M0); (T4, N2, M0); (T4, N3, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  N3: Lung cancer with metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Metastatic Lung Non-Small Cell Squamous Carcinoma

A squamous non-small cell carcinoma that arises from the lung and has metastasized to another anatomic site.


Locally Advanced Lung Non-Small Cell Squamous Carcinoma

A non-small cell squamous carcinoma of the lung that has spread from its original site of growth to nearby tissues or lymph nodes.


Lung Cancer by AJCC v6 Stage

A term that refers to the staging of lung carcinoma according to the American Joint Committee on Cancer, 6th edition.


Lung Carcinoma Metastatic in the Central Nervous System

A carcinoma that has spread to the central nervous system from its original site in the lung, through the hematogenous route.


Stage II Lung Cancer AJCC v6

Stage II includes: IIA (T1, N1, M0) and IIB (T2, N1, M0) or (T3, N0, M0).  T1: Tumor is 3 cm or less in greatest dimension, surrounded by lung or visceral pleura, and without bronchoscopic evidence of invasion more proximal than the lobar bronchus.  T2: Tumor has any of the following features of size or extent: more than 3 cm in greatest dimension; involves the main bronchus, 2 cm or more distal to the carina; invades the visceral pleura; associated with atelectasis or obstructive pneumonitis that extends to the hilar region but does not involve the entire lung.  T3: Tumor (of any size) directly invades any of the following: chest wall (including superior sulcus tumors), diaphragm, mediastinal pleura, parietal pericardium; or tumor in the main bronchus less than 2 cm distal to the carina but without involvement of the carina; or associated atelectasis or obstructive pneumonitis of the entire lung. N0: No regional lymph node metastasis.  N1: Metastasis to ipsilateral peribronchial and/or ipsilateral hilar lymph nodes, and intrapulmonary nodes including involvement by direct extension of the primary tumor. M0: No distant metastasis. (AJCC 6th ed.)


Stage IV Lung Small Cell Carcinoma AJCC v7


Refractory Lung Non-Squamous Non-Small Cell Carcinoma

Non-squamous non-small cell lung carcinoma that is resistant to treatment.


Stage III Lung Cancer AJCC v8

Stage III includes: IIIA: (T1a, N2, M0); (T1b, N2, M0); (T1c, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T4, N0, M0); (T4, N1, M0); IIIB: (T1a, N3, M0); (T1b, N3, M0); (T1c, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N2, M0); (T4, N2, M0); IIIC: (T3, N3, M0); (T4, N3, M0). T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension. T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. T4: Tumor measuring more than 7 cm or tumor of any size invading one or more of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina; separate tumor nodule(s) in an ipsilateral lobe different from that of the primary. N0: No regional lymph node metastases. N1: Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension. N2: Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s). N3: Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s). M0: No distant metastasis. (AJCC 8th ed.)